What is the Nektar Therapeutics stock price forecast?

Nektar Therapeutics is currently trading at $60.27. View real-time AI analysis on Alpha Lenz.

What is Nektar Therapeutics insider trading activity?

View the latest insider trading data for Nektar Therapeutics on Alpha Lenz.

What is Nektar Therapeutics's P/E ratio?

Nektar Therapeutics's P/E ratio is -6.2.

Nektar Therapeutics

NASDAQ · NKTR

$60.27-0.88(-1.44%)Pre-market

Ask about Nektar Therapeutics's future dividend policy...

Alpha Chat Insight

“Nektar Therapeutics trades at a P/E of -6.2 (undervalued) with modest ROE of -217.9%.”

Ask for details →

Company Overview

Nektar Therapeutics is a biopharmaceutical company engaged in the development of innovative drugs to address significant unmet medical needs. Its primary function involves researching and creating therapies using its proprietary polymer conjugate technology, which optimizes drug molecules to improve their efficacy and safety. Nektar's contributions span a range of therapeutic areas, including oncology, pain management, and autoimmune diseases. The company's strategic collaborations with leading pharmaceutical companies enhance its ability to bring novel treatments to market. In the financial markets, Nektar Therapeutics represents a key player in the pharmaceutical sector, providing essential medical advancements through its robust pipeline of drug candidates. This focus on addressing complex health conditions underlines its importance within the broader healthcare industry, making it a significant entity in driving innovation and potential breakthroughs.

CEOMr. Howard W. Robin

Websitehttps://www.nektar.com

SectorHealthcare

IndustryBiotechnology

Employees61

Company Statistics

FY 2025

Profile

$1.02BMarket Cap

$55.23MRevenue

0.00Shares Out

61Employees

Margins

100.00%Gross

-215.36%EBITDA

-236.77%Operating

-281.52%Pre-Tax

-297.07%Net

Valuation

-6.20P/E

11.32P/B

18.41EV/Sales

-9.14EV/EBITDA

-4.87P/FCF

Growth (CAGR)

-15.66%Rev 3Yr

-18.43%Rev 5Yr

N/AOp Inc 3Yr

N/AOp Inc 5Yr

N/ANet Inc 3Yr

N/ANet Inc 5Yr

Returns

-56.17%ROA

-217.94%ROE

-44.26%ROIC

Financial Health

$15.12MCash & Cash Equivalents

$175.46MNet Debt

212.14%Debt/Equity

N/AInterest Cov

Alpha Chat Insight

“Nektar Therapeutics trades at a P/E of -6.2 (undervalued) with modest ROE of -217.9%.”

Ask for details →

Frequently Asked Questions

Nektar Therapeutics (ticker: NKTR) is a company listed on NASDAQ in the Healthcare sector (Biotechnology). It has approximately 61 employees. Market cap is $1.0B.

The current price is $60.27 with a P/E ratio of -6.2x and P/B of 11.32x.

ROE is -217.94% and operating margin is -236.77%. Annual revenue is $55M.